The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Mineralys Therapeutics Inc shares valued at $8,100,000 were purchased by Samsara BioCapital GP, LLC on Mar 13 ’25. At $13.50 per share, Samsara BioCapital GP, LLC acquired 600,000 shares. The insider’s holdings grew to 5,674,916 shares worth approximately $94.94 million following the completion of this transaction.
Also, AKKARAJU SRINIVAS purchased 600,000 shares, netting a total of over 8,100,000 in proceeds. Following the buying of shares at $13.50 each, the insider now holds 5,674,916 shares.
Before that, RA CAPITAL MANAGEMENT, L.P. had added 1,296,296 shares to its account. In a trade valued at $17,499,996, the Director bought Mineralys Therapeutics Inc shares for $13.50 each. Upon closing the transaction, the insider’s holdings increased to 1,296,296 shares, worth approximately $71.61 million.
As published in their initiating research note from H.C. Wainwright on July 10, 2024, Mineralys Therapeutics Inc [MLYS] has been a Buy and the price target has been revised to $30. Analysts at Goldman started covering the stock with ‘”a Buy”‘ outlook in a report released in early April. As of March 07, 2023, Wells Fargo has initiated its “an Overweight” rating for MLYS. Earlier on March 07, 2023, Stifel initiated its rating. Their recommendation was “a Buy” for MLYS stock.
Analyzing MLYS Stock Performance
During the last five days, there has been a surge of approximately 23.93%. Over the course of the year, Mineralys Therapeutics Inc shares have jumped approximately 35.91%. Shares of the company reached a 52-week high of $18.38 on 03/19/25 and a 52-week low of $8.24 on 02/25/25. A 50-day SMA is recorded $10.81, while a 200-day SMA reached $12.14.
Support And Resistance Levels for Mineralys Therapeutics Inc (MLYS)
According to the 24-hour chart, there is a support level at 16.27, which, if violated, would cause prices to drop to 15.81. In the upper region, resistance lies at 17.24. The next price resistance is at 17.75. RSI (Relative Strength Index) is 74.53 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 3.22, which suggests the price will increase in the coming days. Percent R is at 17.02%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
